• Early childhood onset epilepsy and moderate-severe intellectual disability is seen in all cases A number of X-linked epilepsies have been described in which females are exclusively, or disproportionately, affected. The most well-delineated is PCDH19-related epilepsy, a condition that typically presents with fever-sensitive focal seizures, often occurring in clusters, and in which developmental problems often become apparent after epilepsy onset. 1 Other examples include CDKL5, 2 KIAA2022, 3 HNRNPH2, 4 and CASK. 5 In contrast to PCDH19, in which (non-mosaic) male mutation carriers are usually asymptomatic, in CDKL5, HNRNPH2, KIAA2022, and CASK, males are presumed to be nonviable, although rare cases of more severely affected males have been described in CDKL5, KIAA2022, and CASK. 2, 3, 5 The SMC1A gene, located at Xp11.22, encodes one of four core subunits that make up the cohesin ring. The cohesin ring plays important roles in cell division, transcription regulation, and DNA repair. 6 Derangements of the cohesin ring are known to cause Cornelia de Lange syndrome (CdLS), a multisystem developmental disorder first described in 1849. 7 Affected individuals are typically microcephalic with striking prenatal and postnatal growth restriction, often associated with feeding difficulties and gastroesophageal reflux. 8 They have a characteristic facial appearance with fine arched eyebrows, synophrys, long philtrum, thin upper vermilion, and low set posteriorly rotated ears. There is variable presence of malformation (limb, cardiac, diaphragmatic, gastrointestinal, and genitourinary). The reported prevalence of epilepsy ranges from 4% to 23%, with no particular seizure pattern described. 9 Approximately 65% of CdLS cases are caused by mutations in genes (NIPBL, SMC1A, SMC3, RAD21, and HDAC8) that encode structural components or regulators of the cohesin ring. 10 To date, 60 cases of CdLS due to SMC1A mutation have been described, with a maleto-female ratio of 1:2.
11 All reported variants have been missense mutations or small in-frame deletions. This led to the previous hypothesis that mutations causing truncation of the SMC1A protein would be either asymptomatic or nonviable. 11 The absence of SMC1A protein truncating mutations in large databases comprised largely of asymptomatic individuals favored the hypothesis that they would be nonviable.
12 However, recently, SMC1A truncation mutations have been described in five cases, all female, none of whom had a clinical diagnosis of CdLS. [13] [14] [15] All five cases developed drug-resistant epilepsy and had severe developmental impairment. Age at presentation with first epileptic seizure ranged from <1 month to 17 months; 4 of 5 cases were reported to have a clustering pattern to the seizures.
Herein we report the phenotypes of 10 new cases of SMC1A truncation-related epilepsy, further delineating the phenotype. Our data help further define SMC1A truncation as a genetic epilepsy with distinct electroclinical features that can occur in cases without typical features of CdLS. We propose that, along with PCDH19, testing of the SMC1A gene should be considered in females with early childhoodonset drug-resistant epilepsy, particularly where there is a clustering pattern to the seizures.
Methods

Ethical compliance
The Deciphering Developmental Disorders (DDD) study has United Kingdom Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC).
Case ascertainment
Eight of the 10 affected cases (cases 1-8) were recruited via United Kingdom NHS Regional Genetics Services to the Deciphering Developmental Disorders (DDD) project (http://www.ddduk.org/). Case 9 was tested postmortem following the genetic result found in her twin sister through DDD. Case 10 was followed in pediatric neurology and genetics due to a severe developmental and epileptic encephalopathy.
A structured proforma, including detailed phenotypic data, was completed by both the clinical geneticist and the pediatric neurologist involved in each case; this was used in conjunction with information in the DDD database.
Sequencing and analysis
For cases 1-8, trio-based exome sequencing was performed as part of the DDD study as described previously. 16, 17 Target capture using Agilent SureSelect 55 MB Exome Plus was performed on saliva-or blood-derived genomic DNA from each affected case and their parents, and was sequenced on Illumina HiSeq. DeNovoGear21 was used to identify de novo sequence variants and Ensembl Variant Effect Predictor (VEP version 2.6, http://www.ense mbl.org/info/docs/tools/vep/index.html) was used to predict the effect of each genomic variant. PolyPhen-2 analysis was carried out at http://genetics.bwh.harvard.edu/pph2/. SIFT analysis was carried out at http://sift.bii.a-star.edu.sg/www/ SIFT_seq_submit2.html (parameters used: Database UniProt-SwissProt2010_09; Median conservation of sequences 3.00; remove sequences >90% identical). Genbank accession for SMC1A is NM_006306.
Case 9 was postmortem sequenced locally for the variant found in her sister following her sister's result through DDD. Case 10 was tested using a custom gene panel of >100 candidate genes or genes associated with the epileptic encephalopathy, microcephaly, and genetic syndromes with seizures.
Results
Clinical findings
We obtained detailed phenotypic information on nine cases with SMC1A truncation. A further case who was more severely affected than all of the others (case 9), was the older sister of case 8; case 9 died at aged 11 months. We were unable to obtain details of her epilepsy other than that she began having seizures in the neonatal period. She had semilobar holoprosencephaly, partial anomalous pulmonary venous drainage, and dysmorphic facial features. Her sister, with the same mutation, had no structural organ anomalies, no dysmorphic features, and a normal magnetic resonance imaging (MRI) brain scan. All 10 cases identified were female, and they all presented with a drug-resistant epilepsy, although two cases eventually became seizure-free (case 2 from age 5 years, and case 4 from age 7 years). Prior to, and after, their genetic diagnosis, none were considered as having CdLS (see Supporting Information:Case histories for further clinical details of each case).
Development
Apart from the two cases who began having seizures in the neonatal period, concerns about developmental delay had clearly arisen prior to the onset of epileptic seizures. All 10 cases have moderate, severe, or profound developmental impairment, with all domains of development affected. None of the cases have any expressive language. One case (case 6) did develop babbling between 1 and 2 years of age before losing this ability following a 45 minute episode of tonic-clonic status epilepticus at the age of 3 years. None of the other cases were felt to have had any regression in their development associated with either epilepsy onset, or any period of poor seizure control. Four of the 10 cases have achieved independent mobility, albeit with significant delay. Three of the 10 cases have cerebral visual impairment.
Seizures
Age at onset of first seizure ranged from the neonatal period to 28 months of age (median 4.5 months). The first epileptic seizure was an afebrile generalized motor seizure (generalized tonic-clonic, or generalized clonic) in five cases, a focal seizure in two cases, a generalized tonic seizure in one case, and generalized tonic-clonic febrile convulsion in one case. Seven cases demonstrated both focal and generalized seizure types, whereas two cases had generalized seizures only. Seven cases demonstrated a clear predisposition for seizures to occur in clusters. For example, case 6 currently has clusters of between 3 and 10 focal-onset seizures, occurring over a period of 24 hours, every 10-21 days, with complete seizure freedom between clusters. Case 8 has clusters of six to seven generalized tonic-clonic seizures occurring two to three times per month. Two cases have had episodes of convulsive status epilepticus, and one case has had episodes of nonconvulsive status epilepticus.
Electroencephalography (EEG)
All nine cases for whom we have seen EEG studies or EEG reports have demonstrated focal or multifocal abnormalities. Typically, the interictal EEGs show independent multifocal spike and sharp-wave complexes seen in both awake and sleep recordings (see Fig. 1B and Fig. 1D ), as well as subclinical runs of generalized spike-wave abnormalities, lasting several seconds (Fig. 1A) . Ictal EEG studies show generalized slowing of background (Fig. 1C) , followed by focal spike discharge widely distributed over one hemisphere (Fig. 1E) . In other EEG studies in the same case, the spike discharge may be over the other hemisphere.
Epilepsy treatment
From this small case series, no single antiepileptic drug has emerged as clearly more efficacious than others. In fact, although six of the referrers reported one or more antiepileptic drug to be particularly efficacious in their case, in all six cases this was a different drug. One case became seizure free shortly after introduction of phenobarbitone, one case became seizure free shortly after introduction of gabapentin, and one case achieved seizure freedom for 1 year after levetiracetam was initiated. In all cases multiple medications were tried (range 4-8). Three cases tried the ketogenic diet; two of them were felt to benefit significantly in terms of seizure control, and one of them remains on it at present (after 4.5 years). Two have tried vagus nerve stimulation, both without perceived benefit.
Growth
Short stature and progressive microcephaly were seen in the majority of cases. Overall, height and head circumference are proportionally small. Most recent height measurement was >2 Z-scores below the mean in seven of nine cases on most recent height measurement, and mean most recent height was À3.0 Z-scores (standard deviation [SD] 1.5). None of the cases had microcephaly at birth, although mean birth occipitofrontal circumference (OFC) was À1.5 Z-scores below the mean. Most recent OFC was >2 Z scores below the mean in eight of nine cases, with a mean most recent OFC of À3.0 Z-scores (SD 1.6). The cases also demonstrated a deceleration in weight gain. Only one of 10 cases had a low birth weight (>2 Z-scores below the mean), although mean birth weight for the 10 cases was À1.29 Z-scores (SD 0.67). However, in five of nine cases the most recent weight was >2 Z-scores below then mean, and the mean most recent weight for the group was À2.2 Z-scores (SD 1.4).
Dysmorphism and associated anomalies
Two cases have no dysmorphic features and no congenital anomalies, and another one has dysmorphic features but no congenital anomalies. Four cases have congenital cardiac anomalies: two atrial septal defect plus ventricular septal defect, one atrial septal defect only, and one partial anomalous pulmonary venous drainage. Two cases have had cleft palate, and two have bifid thoracic vertebrae. From photographs the primary authors have seen, there appears to be a characteristic facial appearance, consisting of a flattened mid-face, a short, upturned nose, and a shallow philtrum (Fig. 2) .
Genetic findings
The phenotypic findings of the 10 cases from our study, along with those of the previously reported five cases are Table 1 . The genetic findings of the 10 new cases are summarized in Table 2 . In all 10 cases the mutation had arisen de novo and was predicted to lead to premature truncation of the SMC1A protein.
Discussion
Analysis of the 10 cases reported herein, and the previously published 5 cases, allows delineation of a distinct epilepsy phenotype associated with SMC1A truncation mutations. Eight of our 10 cases were recruited from a large cohort of patients who had been referred for genetic investigation of a developmental disorder (the DDD study), not specifically for epilepsy. 17 Despite the broad entry criteria for the DDD study, all the SMC1A truncation cases identified from this cohort have been found to have a severe drugresistant epilepsy, suggesting that the correlation between SMC1A truncation and the epilepsy phenotype is strong. All five previously reported cases in the literature also had drug-resistant epilepsy. [13] [14] [15] In addition, Hansen et al. reported a female with a de novo splice-site mutation in SMC1A who had infantile-onset epilepsy characterized by convulsive seizures "occurring in impressive clusters lasting 24-48 h. 18 " In their discussion, Hansen et al. commented that although the diagnosis of Cornelia de Lange syndrome was not considered initially, "retrospectively the girl's symptoms and facial gestalt [were] compatible with mild Cornelia de Lange syndrome (CdLS)." We argue that SMC1A truncation does not represent a mild form for CdLS, since these female patients are affected by a more severe developmental disorder than is typical for CdLS caused by SMC1A variants.
The presence of seizure clustering is a strong theme that has emerged in our cases. Seven of 10 cases were noted to have seizure clustering. Seizure clustering was also noted in four of five of the previously reported cases. The only other genetic epilepsy for which seizure clustering has emerged as a prominent feature is PCDH19-related epilepsy. As with SMC1A, PCDH19-related epilepsy is an X-linked disorder, affecting mostly females. The PCDH19 phenotype has now been well defined, and can be summarized as follows: normal development before onset of seizures; seizure onset between 3 months and 3 years (median 11 months); 19 clusters of convulsive seizures that are markedly fever sensitive; and progression to multiple seizure types including focal seizures and absences. 1 Developmental stagnation or regression may be noted after epilepsy onset, although up to 40% of PCDH19 cases continue to have normal development. 19, 20 Dysmorphism and malformation are not commonly associated with PCDH19.
21
Epilepsy onset and seizure clustering are remarkably similar in these SMC1A cases to those seen in PCDH19-related epilepsy. Seizure onset was from <4 weeks to 28 months (median five months). Although bilateral motor seizures predominated, nine of 15 had multiple seizure types. Despite certain similarities, a number of features distinguish SMC1A truncation-related epilepsy from PCDH19. From our 10 cases and the five previously reported cases, 12 of 15 were noted to have dysmorphic features and six of 15 had malformations (cardiac, vertebral, and palatal). These cases are also notable for short stature, a marked progressive microcephaly, and for the presence of a moderate to severe developmental impairment, which clearly preceded seizures in those cases with later-onset epilepsy. In terms of their epileptic seizures, these SMC1A truncation cases do not appear to demonstrate the same degree of fever sensitivity as is seen in PCDH19. Furthermore, myoclonic seizures, hemiclonic seizures, and tonic seizures were reported in multiple cases in this series, but these seizure types are not typically seen in PCDH19-related epilepsy. 20 There are phenotypic similarities between the cases reported here and CdLS, including short stature, microcephaly and developmental delay, as well as dysmorphic features and congenital anomalies in some. Four of our cases had structural cardiac anomalies, including atrial septal defect (ASD) and ventricular septal defect (VSD). A wide variety of structural cardiac defects are seen in CdLS, including ASD and VSD. Pulmonary stenosis, not seen in any of our cases, is the most frequently reported cardiovascular anomaly in CdLS. 22, 23 Bifid vertebrae, seen in two of our cases, are not a frequently reported feature of CdLS.
11
What appears to distinguish SMC1A truncation carriers most from the typical CdLS phenotype is the absence of the characteristic facial features, and the severity of the epilepsy and developmental disorder. Although not a core feature of the syndrome, epilepsy is seen more frequently in CdLS than in the general population, with the estimated prevalence in various reports ranging from 4% to 23%. 9 Although epilepsy does not appear to be more frequently seen in SMC1A-related CdLS than in CdLS due to mutations in other cohesin complex genes, 10 it is notable that the majority of, although not all, male SMC1A cases reported have epilepsy as a feature. [24] [25] [26] [27] Whether SMC1A truncation should be considered separate from CdLS, or as a subtype of CdLS, is a matter for debate. It is notable that we have shown that SMC1A truncation can cause a severe developmental disorder and drugresistant epilepsy in cases where CdLS was not otherwise considered. This may have implications for practice when clinicians are considering, and interpreting, genetic testing. The underlying pathophysiology of CdLS caused by SMC1A mutations is not fully understood. SMC1A is a structural component of the cohesin ring, which binds to chromatin and plays an important role in the transcriptional regulation of a large number of other genes. 28 There are 60 published cases of SMC1A-related CdLS (35 female and 25 male), and all reported variants are either missense variants or deletions that preserve the reading frame of the protein. 11, [24] [25] [26] [27] [29] [30] [31] [32] [33] In those cases in which there is familial inheritance of an SMC1A mutation, males demonstrate a more severe phenotype than females. 24 Functional studies using human lymphoblastoid cell lines of CdLS patients and healthy controls have demonstrated that in CdLS, mutant SMC1A is almost fully transcribed and incorporated into the cohesin complex. 29 Because mutant SMC1A would be present in all male cells, whereas in females it would be present only in those cells in which the mutated SMC1A allele is not inactivated, this could explain why male SMC1A CdLS patients appear to be more severely affected than females within the same family. However, SMC1A appears to escape inactivation in some, but not all, females, 34 leading to a hypothesis that mutant SMC1A may exert a dominant negative effect in female CdLS cases. 29 The absence of any reported males with SMC1A truncation mutations implies that complete SMC1A deficiency is incompatible with viability. The mechanism of pathogenesis in females with SMC1A truncation can only be speculated. Lebrun et al. 15 demonstrated that in their female case of SMC1A loss-of-function there was a reduced level of SMC1A transcript. However, if SMC1A does escape X-inactivation, then haploinsufficiency is unlikely to be the causative mechanism because female haploinsufficient cells would have the equivalent of a normal male complement of SMC1A. 35 It is possible that truncated SMC1A is transcribed and translated, escapes nonsense-mediated decay, and exerts a dominant negative effect. To gain a greater understanding of the mechanism would require full investigation of human SMC1A inactivation (including specifically in relevant tissues) and the extent to which truncated transcripts undergo nonsense-mediated decay. Another valuable line of inquiry would be further definition of the role of SMC1A as a transcriptional regulator, whether such transcriptional regulation follows a cyclical pattern, and how this may relate to the clustering pattern of seizures seen.
Finally, it is interesting to note that despite a recent proliferation of large exome sequencing studies investigating children with early onset epilepsy, SMC1A has not emerged as an important gene until now. One reason for this may be that recruitment to previous studies has focused on defined electroclinical syndromes such as Ohtahara syndrome, infantile spasms, Dravet syndrome, Lennox-Gastaut syndrome, and epilepsy with myoclonic atonic seizures. [36] [37] [38] [39] [40] This series demonstrates that through the investigation of a broader group of children with developmental disorders, genetic syndromes with well-defined phenotypes can emerge.
Summary
SMC1A-truncation mutations are seen only in females, and cause a condition in which the typical features of CdLS are often absent. These patients are all affected by a moderate-to-severe developmental impairment and a drug-resistant epilepsy, which characteristically demonstrates a clustering pattern. Further investigation into how SMC1A truncation leads to this phenotype is required. It is likely that disrupted transcriptional regulation of other genes plays an important role.
